source
- Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus KeytrudaAt the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with p…
- FDA releases details on accelerated approval process for personalized gene therapiesThe U.S. Food and Drug Administration has issued additional guidance on a faster approval pathway designed for personalized gene therapies. The new details outline how sponsors can seek expedited r…